β-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism.
Animals
Cell Differentiation
/ genetics
Cell Line, Tumor
Cell Movement
Cell Proliferation
Ceramides
/ metabolism
Down-Regulation
Galactosylceramidase
/ genetics
Gene Silencing
Humans
Lung Neoplasms
/ secondary
Melanocytes
/ cytology
Melanoma
/ metabolism
Mice
Mice, Inbred BALB C
Mice, Inbred NOD
Mice, SCID
Neoplasm Invasiveness
Skin Neoplasms
/ metabolism
Sphingolipids
/ metabolism
Sphingomyelin Phosphodiesterase
/ metabolism
Up-Regulation
Zebrafish
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 11 2020
15 11 2020
Historique:
received:
28
10
2019
revised:
15
07
2020
accepted:
25
09
2020
pubmed:
2
10
2020
medline:
13
2
2021
entrez:
1
10
2020
Statut:
ppublish
Résumé
Disturbance of sphingolipid metabolism may represent a novel therapeutic target in metastatic melanoma, the most lethal form of skin cancer. β-Galactosylceramidase (GALC) removes β-galactose from galactosylceramide and other sphingolipids. In this study, we show that downregulation of
Identifiants
pubmed: 32998995
pii: 0008-5472.CAN-19-3382
doi: 10.1158/0008-5472.CAN-19-3382
doi:
Substances chimiques
Ceramides
0
Sphingolipids
0
SMPD3 protein, human
EC 3.1.4.12
Sphingomyelin Phosphodiesterase
EC 3.1.4.12
Galactosylceramidase
EC 3.2.1.46
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5011-5023Informations de copyright
©2020 American Association for Cancer Research.
Références
Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51–65.
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46:270–83.
Mort RL, Jackson IJ, Patton EE. The melanocyte lineage in development and disease. Development. 2015;142:620–32.
Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18:33–50.
Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2013;13:51–65.
Bizzozero L, Cazzato D, Cervia D, Assi E, Simbari F, Pagni F, et al. Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway. Cell Death Differ. 2014;21:507–20.
Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S, et al. Sphingomyelin Synthase 1 (SMS1) downregulation is associated with sphingolipid reprogramming and a worse prognosis in Melanoma. Front Pharmacol. 2019;10:443.
Shirane K, Kuji R, Tareyanagi C, Sato T, Kobayashi Y, Furukawa S, et al. Gene expression levels of beta4-galactosyltransferase 5 correlate with the tumorigenic potentials of B16-F10 mouse melanoma cells. Glycobiology. 2014;24:532–41.
Tang Y, Cao K, Wang Q, Chen J, Liu R, Wang S, et al. Silencing of CerS6 increases the invasion and glycolysis of melanoma WM35, WM451 and SK28 cell lines via increased GLUT1-induced downregulation of WNT5A. Oncol Rep. 2016;35:2907–15.
Ferrer P, Asensi M, Priego S, Benlloch M, Mena S, Ortega A, et al. Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma. J Biol Chem. 2007;282:2880–90.
Suzuki K, Suzuki Y. Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase. Proc Natl Acad Sci U S A. 1970;66:302–9.
Won JS, Singh AK, Singh I. Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease. J Neurosci Res. 2016;94:990–1006.
Zizioli D, Guarienti M, Tobia C, Gariano G, Borsani G, Bresciani R, et al. Molecular cloning and knockdown of galactocerebrosidase in zebrafish: new insights into the pathogenesis of Krabbe's disease. Biochim Biophys Acta. 2014;1842:665–75.
White RM, Zon LI. Melanocytes in development, regeneration, and cancer. Cell Stem Cell. 2008;3:242–52.
White RM, Sessa A, Burke C, Bowman T, LeBlanc J, Ceol C, et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell. 2008;2:183–9.
Choi J, Dong L, Ahn J, Dao D, Hammerschmidt M, Chen JN. FoxH1 negatively modulates flk1 gene expression and vascular formation in zebrafish. Dev Biol. 2007;304:735–44.
Coltrini D, Di Salle E, Ronca R, Belleri M, Testini C, Presta M. Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR. Angiogenesis. 2013;16:469–77.
Cingolani F, Casasampere M, Sanllehi P, Casas J, Bujons J, Fabrias G. Inhibiton of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. J Lipid Res. 2014;55:1711–20.
Simbari F, McCaskill J, Coakley G, Millar M, Maizels RM, Fabriás G, et al. Plasmalogen enrichment in exosomes secreted by a nematode parasite versus those derived from its mouse host: implications for exosome stability and biology. J Extracell Vesicles. 2016;5:30741.
Nakajima K, Akiyama H, Tanaka K, Kohyama-Koganeya A, Greimel P, Hirabayashi Y. Separation and analysis of mono-glucosylated lipids in brain and skin by hydrophilic interaction chromatography based on carbohydrate and lipid moiety. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1031:146–53.
Stoletov K, Kato H, Zardouzian E, Kelber J, Yang J, Shattil S, et al. Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci. 2010;123:2332–41.
Tobia C, Gariano G, De Sena G, Presta M. Zebrafish embryo as a tool to study tumor/endothelial cell cross-talk. Biochim Biophys Acta. 2013;1832:1371–7.
Ceol CJ, Houvras Y, White RM, Zon LI. Melanoma biology and the promise of zebrafish. Zebrafish. 2008;5:247–55.
Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, et al. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. Mol Cancer Ther. 2013;12:2760–71.
Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest. 2002;109:987–91.
Suzuki K. The twitcher mouse: a model for Krabbe disease and for experimental therapies. Brain Pathol. 1995;5:249–58.
Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, et al. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem. 2002;277:41128–39.
Rozenberg GI, Monahan KB, Torrice C, Bear JE, Sharpless NE. Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation. Melanoma Res. 2010;20:361–71.
Vachtenheim J, Ondrusova L. Microphthalmia-associated transcription factor expression levels in melanoma cells contribute to cell invasion and proliferation. Exp Dermatol. 2015;24:481–4.
Simmons JL, Pierce CJ, Al-Ejeh F, Boyle GM. MITF and BRN2 contribute to metastatic growth after dissemination of melanoma. Sci Rep. 2017;7:10909.
Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006;12:406–14.
Ordonez NG. Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update. Hum Pathol. 2014;45:191–205.
Tandler N, Mosch B, Pietzsch J. Protein and non-protein biomarkers in melanoma: a critical update. Amino Acids. 2012;43:2203–30.
Suzuki K. Twenty five years of the “psychosine hypothesis”: a personal perspective of its history and present status. Neurochem Res. 1998;23:251–9.
Belleri M, Ronca R, Coltrini D, Nico B, Ribatti D, Poliani PL, et al. Inhibition of angiogenesis by beta-galactosylceramidase deficiency in globoid cell leukodystrophy. Brain. 2013;136:2859–75.
Tominaga K, Matsuda J, Kido M, Naito E, Yokota I, Toida K, et al. Genetic background markedly influences vulnerability of the hippocampal neuronal organization in the “twitcher” mouse model of globoid cell leukodystrophy. J Neurosci Res. 2004;77:507–16.
Chatterjee S, Pandey A. The Yin and Yang of lactosylceramide metabolism: implications in cell function. Biochim Biophys Acta. 2008;1780:370–82.
Visigalli I, Ungari S, Martino S, Park H, Cesani M, Gentner B, et al. The galactocerebrosidase enzyme contributes to the maintenance of a functional hematopoietic stem cell niche. Blood. 2010;116:1857–66.
Clarke CJ. Neutral sphingomyelinases in cancer: friend or foe?. Adv Carcer Res. 2018;140:97–119.
Ito H, Murakami M, Furuhata A, Gao S, Yoshida K, Sobue S, et al. Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta. 2009;1789:681–90.
Shamseddine AA, Airola MV, Hannun YA. Roles and regulation of neutral sphingomyelinase-2 in cellular and pathological processes. Adv Biol Regul. 2015;57:24–41.
Shamseddine AA, Clarke CJ, Carroll B, Airola MV, Mohammed S, Rella A, et al. P53-dependent upregulation of neutral sphingomyelinase-2: role in doxorubicin-induced growth arrest. Cell Death Dis. 2015;6:e1947.
Lum MA, Barger CJ, Hsu AH, Leontieva OV, Black AR, Black JD. Protein kinase Cα (PKCα) is resistant to long term desensitization/down-regulation by prolonged diacylglycerol stimulation. J Biol Chem. 2016;291:6331–46.
Lau E, Feng Y, Claps G, Fukuda MN, Perlina A, Donn D, et al. The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation. Sci Signal. 2015;8:ra124.
Lau E, Kluger H, Varsano T, Lee K, Scheffler I, Rimm DL, et al. PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell. 2012;148:543–55.
Takashima A, English B, Chen Z, Cao J, Cui R, Williams RM, et al. Protein kinase Cdelta is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol. 2014;9:1003–14.
Stoffel W, Hammels I, Jenke B, Binczek E, Schmidt-Soltau I, Brodesser S, et al. Neutral sphingomyelinase (SMPD3) deficiency disrupts the Golgi secretory pathway and causes growth inhibition. Cell Death Dis. 2016;7:e2488.
Kim HY, Lee H, Kim SH, Jin H, Bae J, Choi HK. Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling. Sci Rep. 2017;7:8864.